HDCN Abstract:  ASN Annual Meeting -- San Francisco  

Hiramatsu T, Furuta S, Kakuta H

Long-Term Effects of Icodextrin on Cardiovascular Parameters in Peritoneal Dialysis Patients with Volume Overload.

ASN Annual Meeting -- San Francisco
J Am Soc Nephrol (Nov) 18:707A 2007

Background and aim: Volemic status and cardiac hypertrophy are risk factors for mortality in peritoneal dialysis (PD) patients. Icodextrin has been used to improve ultrafiltration (UF) without further dextrose load in PD patients. However, little is known for its long-term effects on cardiovascular parameters such as left ventricular mass index (LVMI) in PD patients with volume overload. The aim of this study was, therefore, to elucidate the effects of icodextrin evaluated by ultrasonographic cardiovascular indices and natriuretic peptides for 2 years in such patients.

Methods: PD patients with congestion were selected for this retrospective analysis. Cardiovascular ultrasonographic (USG) indices and natriuretic peptides were measured every 6 months. Data available from a total of 18 patients for 1 year before and 2 years after the start of icodextrin use were analyzed.

Results: 1) The average age was 55.9 years. 2) The average PD duration was 33.5 months. 3) Cardiac hypertrophy assessed by LVMI and IVS+PWT (interventricular septum+posterior LV thickness) decreased significantly after icodextrin use for 2 years. 3) The values for IMT and IMA at the start had deteriorated in comparison with those at 1 year before the start of icodextrin. 4) None of E/A (ratio of peak early diastolic filling velocity to peak filling velocity at atrial contract), RWT (relative cardiac wall thickness), IMT (intima-media thickness of cervical artery) or IMA (intima-media area of cervical artery) showed any statistically significant changes after icodextrin use. 5) Atrial natriuretic peptide (ANP) was lower after icodextrin use for 1 and 2 years. 5) Brain natriuretic peptide (BNP) was lower for 2 years although its statistical difference was achieved only for the first year. 6) There were statistically significant increases in both daily UF volume and daily total water removal, whereas significant decreases in daily urinary volume over time.

Conclusion: Cardiac hypertrophy evaluated by USG and natriuretic peptides were improved in congestive PD patients after icodextrin use, with consistently increased total water removal over time.

The poster for this abstract is available for viewing. YOU MUST SIGN IN FIRST at the ASN Posters2View website: (you need to type in a separate username and password of your choosing). If you are not signed in, the direct link to the poster below will not work!

Once signed in, you can access the poster for this abstract directly at this link.


Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.